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Background
Hereditary angioedema (HAE) is a rare disorder charac-
terized by a congenital deficiency of the C1-inhibitor. It
is a potentially fatal illness as laryngeal edema may lead
to asphyxiation. Treatment of HAE is mainly performed
with C1-inhibitor concentrate, icatibant, attenuated
androgens, and antifibrinolytic agents. We conducted a
systematic review to evaluate the efficacy and safety of a
purified, pasteurized C1-inhibitor concentrate in the
treatment of patients with type I or II HAE.
Method
An electronic search of five databases (Medline,
EMBASE, Biosis Previews, CINAHL and the Cochrane
Library) was performed with no language or date
restrictions applied. Two reviewers used pre-defined cri-
teria for inclusion of studies and the data were tabulated
and analyzed. The data were found to be inappropriate
for meta-analysis, and thus a qualitative synthesis was
performed.
Results
We found a total of 63 studies that met our inclusion
criteria. Treatment with the C1-inhibitor concentrate
was consistently associated with clinically significant
reductions in both the time to onset of symptom relief
and duration of acute attacks. There were no cases of
angioedema in patients who received the C1-inhibitor
concentrate as short-term prophylaxis, and use of the
C1-inhibitor concentrate as a long-term prophylactic
agent resulted in a significant decrease in the frequency
of attacks. No serious AEs were reported in any patients
who were treated with the C1-inhibitor concentrate, and
there were no treatment-related AEs as far as the injec-
tions were performed correctly. Treatment with the C1-
inhibitor concentrate was not associated with transmis-
sion of viruses or development of autoantibodies.
Conclusion
Results of this systematic review found the C1-inhibitor
concentrate to be an effective option in the treatment of
acute HAE attacks, and as a short- and long-term pro-
phylactic agent.
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